Monoclonal antibodies in the treatment of metastatic carcinoma to the liver: updated report of a pilot study including leukapheresis.
Twenty-two patients who had failed conventional treatment for advanced colorectal carcinoma metastatic to the liver were entered in this study. Survival from the date the hepatic disease was documented and ranged from 3 to 62 months, with an average of 20 months. Notably, 8 of the 22, or 36%, lived 24 months or more. Four patients, or 18%, survived 3 to 5 years after diagnosis of hepatic metastasis.
Hill
B S
BS
Department of Radiation Oncology, Allegheny University of the Health Sciences, Hahnemann Division, Philadelphia, Pennsylvania 19102, USA.
Minard
T
T
Brady
L W
LW
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D015179:Colorectal Neoplasms / Q000473:pathology*; D005260:Female; D006801:Humans; D007937:Leukapheresis; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D015996:Survival Rate
D000911:Antibodies, Monoclonal